Xbrane Biopharma publishes 2016 annual report






Press release 2017-04-28

Xbrane Biopharma ABs annual report for 2016 is now available at the comapnys website, www.xbrane.com. The annual report is distributed to the shareholders and others that made such request. The annual report can also be ordered from Xbrane Biopharma on the following adress:

Xbrane Biopharma AB

Banvaktsvägen 22

17148 Solna


Or via e-mail: ir@xbrane.com

Xbrane Biopharma is a biotechnology company in the commercial phase which develops and manufactures biosimilars and generic long-acting injectables. The aim of the company is to make difficult to manufacture pharmaceuticals available for the global population based on unique technology platforms which enable cost-effective production. Xbrane has a patented protein production platform with up to eight times higher productivity compared with standard systems in E.coli, and world-leading expertise within development and production of microsphere-based pharmaceuticals which have a long-acting effect in the body. Xbrane's head office is located in Stockholm and the company has research and development facilities in Sweden and Italy. Xbrane has been listed on Nasdaq First North since 3 February 2016 under the ticker XBRANE and Avanza Bank AB is Xbrane's certified advisor. For further information, please visit www.xbrane.com.

This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 April 28 2017.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Xbrane Biopharma AB via Globenewswire